Literature DB >> 23453512

Glaucoma severity and medication adherence in a county hospital population.

Cindy Ung1, Elisa Zhang, Tatyana Alfaro, Yohko Murakami, Monica Zhang, Michael I Seider, Shan C Lin, Kuldev Singh.   

Abstract

OBJECTIVE: To assess the association between disease severity and adherence with glaucoma medications in a county hospital population.
DESIGN: Cross-sectional study. PARTICIPANTS: A total of 126 patients diagnosed with glaucoma receiving intraocular pressure (IOP)-lowering medication were recruited from the San Francisco General Hospital Ophthalmology Clinic.
METHODS: Subjects completed an oral questionnaire to assess demographic information, knowledge of glaucoma, and perceptions of glaucoma medication adherence. Glaucoma disease severity was classified according to the American Academy of Ophthalmology's Preferred Practice Pattern guidelines. Medication adherence was measured for each patient by obtaining pharmacy refill data and calculating medication possession ratio (MPR), that is, the ratio of total days' supply of medication during a 365-day period. Adherence was measured retrospectively over the 18-month period before study entry. Subjects with an MPR >80% were considered adherent. MAIN OUTCOME MEASURE: Medication adherence.
RESULTS: Subjects with mild or moderate glaucoma were more likely to be nonadherent to their prescribed glaucoma medications than those with severe disease (adjusted odds ratio [OR], 1.54; 95% confidence interval [CI], 1.03-2.31; P = 0.04). Age, gender, race, education level, years of glaucoma, number of medications, and glaucoma diagnosis were not found to be statistically significantly associated with adherence.
CONCLUSION: Patients with severe glaucoma were more likely to adhere to their topical IOP-lowering medication regimen than those with milder glaucomatous disease. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23453512      PMCID: PMC3674151          DOI: 10.1016/j.ophtha.2012.11.026

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  39 in total

1.  A population-based survey of the prevalence and types of glaucoma in Nepal: the Bhaktapur Glaucoma Study.

Authors:  Suman S Thapa; Indira Paudyal; Shankar Khanal; Shankha N Twyana; Govinda Paudyal; Reeta Gurung; Sanduk Ruit; Ger H M B van Rens
Journal:  Ophthalmology       Date:  2012-02-02       Impact factor: 12.079

2.  Trouble getting started: predictors of primary medication nonadherence.

Authors:  Michael A Fischer; Niteesh K Choudhry; Gregory Brill; Jerry Avorn; Sebastian Schneeweiss; David Hutchins; Joshua N Liberman; Troyen A Brennan; William H Shrank
Journal:  Am J Med       Date:  2011-11       Impact factor: 4.965

3.  Optic disc parameters and onset of glaucomatous field loss. I. Methods and progressive changes in disc morphology.

Authors:  A Sommer; I Pollack; A E Maumenee
Journal:  Arch Ophthalmol       Date:  1979-08

4.  The practical clinical appraisal of the optic disc in glaucoma: the natural history of cup progression and some specific disc-field correlations.

Authors:  R M Read; G L Spaeth
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1974 Mar-Apr

5.  Visual loss in a glaucoma clinic. I. Sociological considerations.

Authors:  G L Spaeth
Journal:  Invest Ophthalmol       Date:  1970-01

6.  Compliance with treatment of patients with chronic open-angle glaucoma.

Authors:  J M MacKean; A R Elkington
Journal:  Br J Ophthalmol       Date:  1983-01       Impact factor: 4.638

7.  The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity.

Authors:  Betsy Sleath; Susan Blalock; David Covert; Jennifer L Stone; Asheley Cockrell Skinner; Kelly Muir; Alan L Robin
Journal:  Ophthalmology       Date:  2011-12       Impact factor: 12.079

8.  Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy.

Authors:  H A Quigley; E M Addicks; W R Green
Journal:  Arch Ophthalmol       Date:  1982-01

9.  The characteristics of glaucoma in Japanese Americans.

Authors:  Melike Pekmezci; Baotran Vo; Annie K Lim; Dean R Hirabayashi; George H Tanaka; Robert N Weinreb; Shan C Lin
Journal:  Arch Ophthalmol       Date:  2009-02

10.  Progression of visual field defects in glaucoma. Relation to compliance with pilocarpine therapy.

Authors:  P A Granström
Journal:  Arch Ophthalmol       Date:  1985-04
View more
  14 in total

1.  Why Patients With Glaucoma Lose Vision: The Patient Perspective.

Authors:  Paula A Newman-Casey; Roni M Shtein; Anne L Coleman; Leon Herndon; Paul P Lee
Journal:  J Glaucoma       Date:  2016-07       Impact factor: 2.503

2.  Visual field-based grading of disease severity in newly diagnosed primary open angle glaucoma patients presenting to a tertiary eye care centre in India.

Authors:  Sharmila Rajendrababu; Oshin Bansal; Sujani Shroff; Vijayalakshmi A Senthilkumar; Mohammed Sithiq Uduman
Journal:  Int Ophthalmol       Date:  2021-05-09       Impact factor: 2.031

3.  Dry eye specific quality of life in veterans using glaucoma drops.

Authors:  Andrew Camp; Sarah R Wellik; Jonathan H Tzu; William Feuer; Kristopher L Arheart; Ananth Sastry; Anat Galor
Journal:  Cont Lens Anterior Eye       Date:  2015-02-24       Impact factor: 3.077

4.  Systemic Barriers in Receiving Electronically Prescribed Glaucoma Medications.

Authors:  Isdin Oke; Avni Badami; Kathryn L Kosteva; Kevin Wu; Manishi A Desai
Journal:  J Glaucoma       Date:  2022-08-10       Impact factor: 2.290

5.  Level of adherence to ocular hypotensive agents and its determinant factors among glaucoma patients in Menelik II Referral Hospital, Ethiopia.

Authors:  Tesfay Mehari; Abeba T Giorgis; Workineh Shibeshi
Journal:  BMC Ophthalmol       Date:  2016-08-02       Impact factor: 2.209

6.  Adherence to treatment in patients with open-angle glaucoma and its related factors.

Authors:  Tayebeh Movahedinejad; Mohsen Adib-Hajbaghery
Journal:  Electron Physician       Date:  2016-09-20

7.  Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol.

Authors:  Masahiro Fuwa; Atsushi Shimazaki; Masafumi Mieda; Naoko Yamashita; Takahiro Akaishi; Takazumi Taniguchi; Masatomo Kato
Journal:  Sci Rep       Date:  2019-05-16       Impact factor: 4.379

Review 8.  Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus.

Authors:  Quang H Nguyen
Journal:  Patient Prefer Adherence       Date:  2014-06-12       Impact factor: 2.711

9.  Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.

Authors:  Masahiro Fuwa; Kenji Ueda; Takahiro Akaishi; Naoko Yamashita; Tomoko Kirihara; Atsushi Shimazaki; Hidetoshi Mano; Kouichi Kawazu
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

10.  Areas and factors associated with patients' dissatisfaction with glaucoma care.

Authors:  Valencia Hui Xian Foo; Sarah En Mei Tan; David Ziyou Chen; Shamira A Perera; Charumathi Sabayanagam; Eva Katie Fenwick; Tina T Wong; Ecosse L Lamoureux
Journal:  Clin Ophthalmol       Date:  2017-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.